Home Cart Sign in  
Chemical Structure| 1038915-60-4 Chemical Structure| 1038915-60-4

Structure of Niraparib
CAS No.: 1038915-60-4

Chemical Structure| 1038915-60-4

*Storage: {[sel_prStorage]}

*Shipping: {[sel_prShipping]}

,{[proInfo.pro_purity]}

Niraparib (MK-4827) is a highly potent and orally bioavailable PARP1 and PARP2 inhibitor with IC50s of 3.8 nM and 2.1 nM, respectively. Niraparib inhibits DNA damage repair, activates apoptosis, and exhibits anti-tumor activity.

Synonyms: MK-4827

4.5 *For Research Use Only !

{[proInfo.pro_purity]}
Cat. No.: {[proInfo.prAm]} Purity: {[proInfo.pro_purity]}

Change View

Size Price VIP Price

US Stock

Global Stock

In Stock
{[ item.pr_size ]} Inquiry {[ getRatePrice(item.pr_usd,item.pr_rate,item.mem_rate,item.pr_is_large_size_no_price, item.vip_usd) ]}

US Stock: ship in 0-1 business day
Global Stock: ship in 5-7 days

  • {[ item.pr_size ]}

In Stock

- +

Please Login or Create an Account to: See VIP prices and availability

US Stock: ship in 0-1 business day
Global Stock: ship in 2 weeks

  • 1-2 Day Shipping
  • High Quality
  • Technical Support
Product Citations

Alternative Products

Product Details of Niraparib

CAS No. :1038915-60-4
Formula : C19H20N4O
M.W : 320.39
SMILES Code : O=C(C1=CC=CC2=CN(C3=CC=C([C@H]4CNCCC4)C=C3)N=C12)N
Synonyms :
MK-4827
MDL No. :MFCD17779309
InChI Key :PCHKPVIQAHNQLW-CQSZACIVSA-N
Pubchem ID :24958200

Safety of Niraparib

GHS Pictogram:
Signal Word:Danger
Hazard Statements:H302-H340
Precautionary Statements:P260-P264-P270-P280-P281-P330-P301+P312-P405-P501

Related Pathways of Niraparib

epigenetics
DNA

Isoform Comparison

Biological Activity

Target
  • PARP1

    PARP1, IC50:3.8 nM

  • PARP2

    PARP2, IC50:2.1 nM

In Vitro:

Cell Line
Concentration Treated Time Description References
SKOV3 10 μM 72 h To evaluate the anti-tumor effect of Niraparib on SKOV3 cells, results showed that Niraparib significantly inhibited cell viability. PMC11851289
OV90 10 μM 72 h To evaluate the anti-tumor effect of Niraparib on OV90 cells, results showed that Niraparib significantly inhibited cell viability. PMC11851289
A2780 10 μM 72 h To evaluate the anti-tumor effect of Niraparib on A2780 cells, results showed that Niraparib significantly inhibited cell viability. PMC11851289
OVCAR8 10 μM 72 h To evaluate the anti-tumor effect of Niraparib on OVCAR8 cells, results showed that Niraparib significantly inhibited cell viability. PMC11851289
A549-RB1-KO 1 μM 72 h A549-RB1-KO cells showed significantly reduced viability after Niraparib treatment, indicating that RB1 deficiency enhances the effect of PARP inhibitors on DNA damage. PMC10721263
A549 1 μM 72 h A549 cells formed more colonies after Niraparib treatment, indicating that RB1 wild-type cells are less sensitive to PARP inhibitors. PMC10721263
H2228 1 μM 72 h H2228 cells formed fewer colonies after Niraparib treatment, indicating that RB1 mutation increased sensitivity to PARP inhibitors. PMC10721263
UWB1.289 10 μM 48 h To investigate the effect of Niraparib on PD-L1 expression, results showed that Niraparib upregulated PD-L1 expression. PMC8499579
SKOV3 10 μM 48 h To investigate the effect of Niraparib on PD-L1 expression, results showed that Niraparib upregulated PD-L1 expression. PMC8499579
LLC PARhigh cells 3 to 12 µM 7 days PARhigh LLC cells died after niraparib treatment, while PARP1KO LLC cells showed only a marginal response at the highest dose (12 µM) PMC9247697
HO8910 10 μM 48 h To evaluate the apoptotic effect of Niraparib combined with berberine on ovarian cancer cells, the results showed that the combination significantly increased apoptosis. PMC5680592
A2780 10 μM 48 h To evaluate the apoptotic effect of Niraparib combined with berberine on ovarian cancer cells, the results showed that the combination significantly increased apoptosis. PMC5680592
ID8 35 μM 48 h To study the growth inhibition and sensitivity of Niraparib on ID8 cells PMC11876957
OVCAR3 45 μM 48 h To study the growth inhibition and sensitivity of Niraparib on OVCAR3 cells PMC11876957
A2780 80 μM 48 h To study the growth inhibition and sensitivity of Niraparib on A2780 cells PMC11876957

In Vivo:

Species
Animal Model
Administration Dosage Frequency Description References
Mice ID8 tumor model Oral 50 mg/kg Once daily for 3 weeks To evaluate the anti-tumor effect of Niraparib in the ID8 tumor model, results showed that Niraparib significantly inhibited tumor growth. PMC11851289
C57BL/6 mice ID8 ovarian cancer model Oral 40 mg/kg 5 days a week for 4 weeks To evaluate the effect of Niraparib on tumor growth, results showed that Niraparib significantly inhibited tumor growth. PMC11459312
C57BL/6j mice Ovarian in situ tumor model Intramuscular injection and oral 50 mg/kg 3 times per week for 4 weeks The combination of P4 and Niraparib significantly prolonged the survival time of mice and reduced tumor volume. PMC11116976
Mice RB1-KO xenograft mouse model Intraperitoneal injection 10 mg/kg Every 2 days for 30 days Niraparib treatment significantly reduced tumor volume and weight in RB1-KO mice, indicating that RB1 mutation enhances the antitumor efficacy of PARP inhibitors. PMC10721263
C57BL/6 mice Ovarian cancer model Oral 25 mg/kg Four times a week for 52 days To investigate the effect of Niraparib on PD-L1 expression and its synergistic effect with PD-L1 blockade, results showed that Niraparib upregulated PD-L1 expression and synergistically inhibited tumor growth with PD-L1 blockade. PMC8499579
Mice NSCLC mouse model Oral 80 mg/kg Once daily for 5 days on and 2 days off per week Niraparib significantly reduced the growth of PARhigh tumors, and this effect was similar in T cell-depleted mice, indicating that the antitumor effect of niraparib is independent of T cells PMC9247697
Nude mice A2780 ovarian cancer xenograft model Oral 40 mg/kg Once daily for 15 days To evaluate the tumor growth inhibitory effect of Niraparib combined with berberine, the results showed that the combination significantly inhibited tumor growth. PMC5680592
C57BL/6JGpt mice ID8 EOC model Oral 50 mg/kg Once a day for 21 days To evaluate the effect of Niraparib on tumor growth and survival in ID8 EOC model mice PMC11876957

Clinical Trial:

NCT Number Conditions Phases Recruitment Completion Date Locations
NCT03705156 Platinum-sensitive Relapsed Ov... More >>arian Cancer Less << Phase 3 Recruiting June 8, 2020 -
NCT03709316 Ovarian Cancer Phase 3 Recruiting June 30, 2021 -
NCT03574779 Ovarian Cancer Phase 2 Recruiting June 2020 United States, Massachusetts ... More >> Dana-Farber Cancer Institute Recruiting Boston, Massachusetts, United States, 02215 United States, Oklahoma Stephenson Cancer Center Recruiting Oklahoma City, Oklahoma, United States, 73104 Less <<
NCT03598270 Recurrent Ovarian Carcinoma Phase 3 Not yet recruiting November 2023 Spain ... More >> Complejo Hospitalario Universitario de A Coruña Not yet recruiting A Coruña, Spain Contact: María Quindós, MD          Principal Investigator: María Quindós, MD          ICO Badalona Not yet recruiting Badalona, Spain Contact: Margarita Romeo, MD          Principal Investigator: Margarita Romeo, MD          H. Clínic Barcelona Not yet recruiting Barcelona, Spain Contact: Lydia Gaba, MD          Principal Investigator: Lydia Gaba, MD          Hospital de la Santa Creu i Sant Pau Not yet recruiting Barcelona, Spain Contact: Cristina Martin, MD          Principal Investigator: Belén Ojeda, MD          Hospital de la Vall d'Hebron Not yet recruiting Barcelona, Spain Contact: Ana Oaknin, MD PhD          Principal Investigator: Ana Oaknin, MD PhD          H Reina Sofía Cordoba Not yet recruiting Cordoba, Spain Contact: Maria Jesus Rubio, MD          Principal Investigator: Maria Jesus Rubio, MD          ICO Girona Not yet recruiting Girona, Spain Contact: Pilar Barretina, MD          Principal Investigator: Pilar Barretina, MD          ICO Hospitalet Not yet recruiting Hospitalet del Llobregat, Spain Contact: Beatriz Pardo, MD          Principal Investigator: Beatriz Pardo, MD          Hospital de León Not yet recruiting León, Spain Contact: Luis Miguel de Sande, MD          Principal Investigator: Luis Miguel de Sande, MD          Clinica Universitaria de Navarra Not yet recruiting Madrid, Spain Contact: Antonio Gonzalez, MD PhD          Principal Investigator: Antonio González, MD PhD          Hospital Clínico San Carlos Not yet recruiting Madrid, Spain Contact: Gloria Marquina, MD          Principal Investigator: Gloria Marquina, MD          Hospital Gregorio Marañon Not yet recruiting Madrid, Spain Contact: Sara Pérez Ramírez, MD          Principal Investigator: Sara Pérez Ramírez, MD          Hospital Universitario La Paz Not yet recruiting Madrid, Spain Contact: Andrés Redondo, MD          Principal Investigator: Andrés Redondo, MD          Hospital Universitario Ramon y Cajal Not yet recruiting Madrid, Spain Contact: Eva Guerra, MD          Principal Investigator: Eva Guerra, MD          H Morales Meseguer Not yet recruiting Murcia, Spain Contact: Helena Garcia, Md          Principal Investigator: Helena García, MD          Complejo Hospitalario Regional de Málaga Not yet recruiting Málaga, Spain Contact: Maria Jose´ Bermejo, MD          Principal Investigator: Maria José Bermejo, MD          Hospital Son Llatzer Not yet recruiting Palma De Mallorca, Spain Contact: María Iglesias González, MD          Principal Investigator: María Iglesias González, MD          Hospital Virgen del Rocio Not yet recruiting Sevilla, Spain Contact: Puri Estévez, MD          Principal Investigator: Puri Estévez, MD          H La Fe de Valencia Not yet recruiting Valencia, Spain Contact: Ana Santaballa, MD          Principal Investigator: Ana Santaballa, MD          Hospital Clínico Universitario de Valencia Not yet recruiting Valencia, Spain Contact: José A Pérez Fidalgo, MD          Principal Investigator: José A Pérez Fidalgo, MD Less <<
NCT02044120 Ewing Sarcoma Phase 1 Active, not recruiting April 2021 United States, California ... More >> Children's Hospital of Los Angeles Los Angeles, California, United States, 90027 United States, Maryland National Cancer Institute Bethesda, Maryland, United States, 20892 United States, Michigan University of Michigan Ann Arbor, Michigan, United States, 48106 United States, Washington Seattle's Children Cancer Center Seattle, Washington, United States, 98101 United Kingdom University College London Hospital London, United Kingdom, W1T 7HA Less <<
NCT03025867 Recurrent Ovarian Cancer APPROVED_FOR_MARKETING - -
NCT03307785 Metastatic Cancer ... More >> Advanced Cancer Solid Tumor Non Small Cell Lung Cancer Metastatic Non Small Cell Lung Cancer Stage IIIB Non Small Cell Lung Cancer Less << Phase 1 Recruiting March 2020 United States, Arizona ... More >> Honor Health Recruiting Scottsdale, Arizona, United States, 85258 Principal Investigator: Jasgit Sachdev, MD          United States, California California Cancer Associates for Research and Excellence (cCare) Recruiting Encinitas, California, United States, 92024 Principal Investigator: Alberto Bessudo, MD          United States, Florida Florida Cancer Specialist Recruiting Sarasota, Florida, United States, 34232 Principal Investigator: Manish Patel, MD          United States, Ohio Gabrail Cancer Center Research Recruiting Canton, Ohio, United States, 44718 Principal Investigator: Nashat Gabrail, MD          United States, Tennessee Tennessee Oncology Recruiting Nashville, Tennessee, United States, 37203 Principal Investigator: Erika Hamilton, MD          United States, Texas MD Anderson Recruiting Houston, Texas, United States, 77030 Principal Investigator: Timothy Yap, MD Less <<
NCT03748641 Metastatic Prostate Cancer Phase 3 Not yet recruiting February 25, 2025 -
NCT03651206 Ovarian Carcinosarcoma ... More >> Endometrial Carcinosarcoma Less << Phase 2 Phase 3 Not yet recruiting January 2023 -
NCT03695380 OVARIAN CANCER Phase 1 Not yet recruiting November 24, 2022 -
NCT03431350 Prostatic Neoplasms, Castratio... More >>n-Resistant Less << Phase 1 Phase 2 Recruiting December 31, 2020 United States, Colorado ... More >> The Urology Center of Colorado Recruiting Denver, Colorado, United States, 80211 United States, New York Memorial Sloan Kettering Cancer Center Recruiting Harrison, New York, United States, 10604 Memorial Sloan Kettering Cancer Center Recruiting New York, New York, United States, 10065 United States, Pennsylvania Thomas Jefferson University Recruiting Philadelphia, Pennsylvania, United States, 19107 United States, South Carolina MUSC-Hollings Cancer Center Recruiting Charleston, South Carolina, United States, 29425 United States, Texas The University of Texas MD Anderson Cancer Center Recruiting Houston, Texas, United States, 77030 United States, Utah University of Utah Huntsman Cancer Institute Withdrawn Salt Lake City, Utah, United States, 84112 United States, Wisconsin University of Wisconsin Carbone Cancer Center Recruiting Madison, Wisconsin, United States, 5379200 Canada, Quebec Centre de Recherche du CHUM Not yet recruiting Montreal, Quebec, Canada, H2X 0A9 Canada British Columbia Cancer Agency Recruiting Vancouver, Canada, V5Z4E6 Israel Asaf Harofe Medical Center Recruiting Beer Yaakov, Israel, 60930 Rambam Medical Center Recruiting Haifa, Israel, 31096 Rabin Medical Center Recruiting Petach Tikva, Israel, 49100 Sheba Medical Center Tel Hashomer Recruiting Ramat Gan, Israel, 52621 Spain Hospital Vall D'Hebron Recruiting Barcelona, Spain, 08035 Hosp. Univ. Fund. Jimenez Diaz Recruiting Madrid, Spain, 28040 Hosp. Univ. Hm Sanchinarro Recruiting Madrid, Spain, 28050 United Kingdom Guy's Hospital Withdrawn London, United Kingdom, SE1 9RT Southampton General Hospital Not yet recruiting Southampton, United Kingdom, SO16 6YD The Royal Marsden NHS Trust Sutton Recruiting Sutton, United Kingdom, SM2 5PT Less <<
NCT03516084 Extensive-stage Small Cell Lun... More >>g Cancer Less << Phase 3 Not yet recruiting May 2022 -
NCT03551171 Ovarian Cancer Phase 1 Active, not recruiting December 30, 2018 China, Beijing ... More >> Beijing Cancer Hospital Beijing, Beijing, China, 100000 China, Guangdong Sun Yat-sen University Cancer Center Guangzhou, Guangdong, China, 510000 China, Heilongjiang Haerbin Medical University Cancer Hospital Harbin, Heilongjiang, China, 150000 China, Hunan Hunan Cancer Hospital Changsha, Hunan, China, 410013 China, Shanghai Fudan University Shanghai Cnacer Center Shanghai, Shanghai, China, 200000 China, Sichuan The West China Second UniversityHospital of Sichuan University Chengdu, Sichuan, China, 610000 Less <<
NCT03404960 Pancreatic Adenocarcinoma Phase 1 Phase 2 Recruiting June 2021 United States, Pennsylvania ... More >> University of Pennsylvania, Abramson Cancer Center Recruiting Philadelphia, Pennsylvania, United States, 19104 Contact: Danielle Karlson    215-220-9704    danielle.Karlson@uphs.upenn.edu    Principal Investigator: Kim Reiss Binder, MD Less <<
NCT03602859 Ovarian Cancer Phase 3 Recruiting July 31, 2023 United States, Alaska ... More >> Alaska Women's Cancer Care Recruiting Anchorage, Alaska, United States, 99508 United States, Connecticut Hartford Hospital Recruiting Hartford, Connecticut, United States, 06102 United States, Louisiana Women's Cancer Care Recruiting Covington, Louisiana, United States, 70433 Willis-Knighton Cancer Center Recruiting Shreveport, Louisiana, United States, 71103 United States, Maryland Holy Cross Hospital Recruiting Silver Spring, Maryland, United States, 20910 United States, Ohio Aultman Hospital Recruiting Canton, Ohio, United States, 44710 United States, South Dakota Avera Cancer Institute Recruiting Sioux Falls, South Dakota, United States, 57105 United States, Washington Kadlec Regional Medical Center Recruiting Kennewick, Washington, United States, 99336 Swedish Medical Center Recruiting Seattle, Washington, United States, 98104 Less <<
NCT02476552 Cancer Phase 1 Completed - Netherlands ... More >> The Netherlands Cancer Institute Amsterdam, Netherlands, 1066 CX Less <<
NCT02655016 Ovarian Cancer Phase 3 Active, not recruiting - -
NCT02354131 Ovarian Cancer Phase 1 Phase 2 Active, not recruiting December 2020 United States, Massachusetts ... More >> Massachusetts General Hospital Boston, Massachusetts, United States Denmark Rigshospitalet Copenhagen, Sjaelland, Denmark, 2100 Less <<
NCT02354586 Ovarian Neoplasms|Ovarian Canc... More >>er Less << PHASE2 COMPLETED 2021-08-23 GSK Investigational Site, Chan... More >>dler, Arizona, 85224, United States|GSK Investigational Site, Phoenix, Arizona, 85016, United States|GSK Investigational Site, Tucson, Arizona, 85710, United States|GSK Investigational Site, Burbank, California, 91505, United States|GSK Investigational Site, Duarte, California, 91010, United States|GSK Investigational Site, Los Angeles, California, 90027, United States|GSK Investigational Site, Los Angeles, California, 90048, United States|GSK Investigational Site, San Francisco, California, 94118, United States|GSK Investigational Site, Santa Barbara, California, 93105, United States|GSK Investigational Site, Stanford, California, 94305-5317, United States|GSK Investigational Site, New Haven, Connecticut, 06510, United States|GSK Investigational Site, Tampa, Florida, 33612, United States|GSK Investigational Site, West Palm Beach, Florida, 33401, United States|GSK Investigational Site, Atlanta, Georgia, 30342, United States|GSK Investigational Site, Chicago, Illinois, 60611, United States|GSK Investigational Site, Chicago, Illinois, 60637, United States|GSK Investigational Site, Indianapolis, Indiana, 46260, United States|GSK Investigational Site, Indianapolis, Indiana, 54244, United States|GSK Investigational Site, Covington, Louisiana, 70433, United States|GSK Investigational Site, New Orleans, Louisiana, 70121, United States|GSK Investigational Site, Baltimore, Maryland, 21202, United States|GSK Investigational Site, Boston, Massachusetts, 02115, United States|GSK Investigational Site, Boston, Massachusetts, 02215, United States|GSK Investigational Site, Burlington, Massachusetts, 01805, United States|GSK Investigational Site, Ann Arbor, Michigan, 48109, United States|GSK Investigational Site, Minneapolis, Minnesota, 55455, United States|GSK Investigational Site, Rochester, Minnesota, 55905, United States|GSK Investigational Site, Springfield, Missouri, 65804, United States|GSK Investigational Site, Hackensack, New Jersey, 07601, United States|GSK Investigational Site, Morristown, New Jersey, 07962-1956, United States|GSK Investigational Site, East Setauket, New York, 11733, United States|GSK Investigational Site, Jamaica, New York, 11432, United States|GSK Investigational Site, Lake Success, New York, 11042, United States|GSK Investigational Site, New York, New York, 10065, United States|GSK Investigational Site, Durham, North Carolina, 27710, United States|GSK Investigational Site, Oklahoma City, Oklahoma, 73104, United States|GSK Investigational Site, Medford, Oregon, 97504-8342, United States|GSK Investigational Site, Wynnewood, Pennsylvania, 19096, United States|GSK Investigational Site, Providence, Rhode Island, 02905, United States|GSK Investigational Site, Nashville, Tennessee, 37203, United States|GSK Investigational Site, Austin, Texas, 78731, United States|GSK Investigational Site, Dallas, Texas, 75390, United States|GSK Investigational Site, Fort Worth, Texas, 76104, United States|GSK Investigational Site, San Antonio, Texas, 78229, United States|GSK Investigational Site, The Woodlands, Texas, 77380, United States|GSK Investigational Site, Tyler, Texas, 75702, United States|GSK Investigational Site, Spokane, Washington, 99202, United States|GSK Investigational Site, Tacoma, Washington, 98405, United States|GSK Investigational Site, Calgary, Alberta, T2N 4N2, Canada|GSK Investigational Site, Toronto, Ontario, M5G 2M9, Canada|GSK Investigational Site, Montreal, Quebec, H1T 2M4, Canada|GSK Investigational Site, Montreal, Quebec, H2L 4M1, Canada|GSK Investigational Site, Montreal, Quebec, H3T 1E2, Canada|GSK Investigational Site, Montreal, Quebec, H4A 3J1, Canada|GSK Investigational Site, Sherbrooke, Quebec, J1H 5N4, Canada Less <<
NCT02657889 Triple Negative Breast Cancer ... More >> Ovarian Cancer Breast Cancer Metastatic Breast Cancer Advanced Breast Cancer Stage IV Breast Cancer Fallopian Tube Cancer Peritoneal Cancer Less << Phase 1 Phase 2 Active, not recruiting February 2019 -
NCT03326193 Ovarian Cancer ... More >> Fallopian Tube Cancer Primary Peritoneal Carcinoma Less << Phase 2 Recruiting September 30, 2021 -
NCT02826512 Breast Cancer PHASE2 TERMINATED 2022-07-01 Antoni van Leeuwenhoek, Amster... More >>dam, 1066 CX, Netherlands|Deventer ziekenhuis, Deventer, Netherlands|Erasmus Medical Center Cancer Institute, Rotterdam, 3015CE, Netherlands Less <<
NCT02924766 Prostatic Neoplasms Phase 1 Active, not recruiting March 7, 2019 United States, California ... More >> West Hollywood, California, United States United States, Kentucky Louisville, Kentucky, United States United States, Oregon Portland, Oregon, United States United States, South Carolina Myrtle Beach, South Carolina, United States Canada, British Columbia Vancouver, British Columbia, Canada Canada, Quebec Montreal, Quebec, Canada Less <<
NCT03308942 Lung Neoplasms Phase 2 Recruiting May 2020 -
NCT02854436 Prostatic Neoplasms PHASE2 COMPLETED 2023-08-16 Tucson, Arizona, United States... More >>|Los Angeles, California, United States|Riverside, California, United States|Sacramento, California, United States|Aurora, Colorado, United States|Denver, Colorado, United States|Evanston, Illinois, United States|Danville, Kentucky, United States|Louisville, Kentucky, United States|New Orleans, Louisiana, United States|Boston, Massachusetts, United States|Detroit, Michigan, United States|Omaha, Nebraska, United States|New York, New York, United States|Durham, North Carolina, United States|Lancaster, Pennsylvania, United States|Philadelphia, Pennsylvania, United States|Myrtle Beach, South Carolina, United States|Houston, Texas, United States|Charlottesville, Virginia, United States|Fairfax, Virginia, United States|Seattle, Washington, United States|Madison, Wisconsin, United States|Camperdown, Australia|Darlinghurst, Australia|East Albury, Australia|Kurralta Park, Australia|Macquarie University, Australia|Melbourne, Australia|Murdoch, Australia|Port Macquarie, Australia|Randwick, Australia|Wahroonga, Australia|Aalst, Belgium|Brussel, Belgium|Charleroi, Belgium|Gent, Belgium|Haine-Saint-Paul, La Louviere, Belgium|Hasselt, Belgium|Kortrijk, Belgium|Liège, Belgium|Namur, Belgium|Ottignies, Belgium|Wilrijk, Belgium|Barretos, Brazil|Belo Horizonte, Brazil|Curitiba, Brazil|Fortaleza, Brazil|Ijui, Brazil|Itajai, Brazil|Joinville, Brazil|Natal, Brazil|Salvador, Brazil|Sao Paulo, Brazil|Vancouver, British Columbia, Canada|Oshawa, Ontario, Canada|Toronto, Ontario, Canada|Montreal, Quebec, Canada|Quebec, Canada|Aarhus N., Denmark|Copenhagen N, Denmark|Herlev, Denmark|Odense C, Denmark|Avignon Cedex 9, France|Besancon, France|Caen, France|Lyon, France|Nice Cedex 2, France|Paris, France|Reims, France|Strasbourg, France|Villejuif Cedex, France|Beer-Sheva, Israel|Haifa, Israel|Kfar Saba, Israel|Ramat Gan, Israel|Zrifin, Israel|Seoul, Korea, Republic of|Alkmaar, Netherlands|Amsterdam, Netherlands|Groningen, Netherlands|Maastricht, Netherlands|Rotterdam, Netherlands|Moscow, Russian Federation|Omsk, Russian Federation|Tomsk, Russian Federation|Barcelona, Spain|Córdoba, Spain|Madrid, Spain|Málaga, Spain|Pozuelo de Alarcon, Spain|Santander, Spain|Santiago de Compostela, Spain|Sevilla, Spain|Valencia, Spain|G?teborg, Sweden|Lund, Sweden|Stockholm, Sweden|Ume?, Sweden|Kaohsiung, Taiwan|Taichung, Taiwan|Tainan, Taiwan|Taipei, Taiwan|Taoyuan County, Taiwan|Blackburn, United Kingdom|Bristol, United Kingdom|Cardiff, United Kingdom|Exeter, United Kingdom|London, United Kingdom|Preston, United Kingdom Less <<
NCT03553004 Pancreatic Cancer Phase 2 Not yet recruiting February 1, 2025 United States, Kansas ... More >> University of Kansas Cancer Center - Clinical Research Center Not yet recruiting Fairway, Kansas, United States, 66208 Contact: kerry hepler    913-945-7552    ctnursenav@kumc.edu    University of Kansas Cancer Center - West Not yet recruiting Kansas City, Kansas, United States, 66112 Contact: Kerry Hepler    913-945-7552    ctnursenav@kumc.edu    University of Kansas Cancer Center - Overland Park Not yet recruiting Overland Park, Kansas, United States, 66210 Contact: kerry hepler    913-945-7552    ctnursenav@kumc.edu    The University of Kansas Cancer Center Not yet recruiting Westwood, Kansas, United States, 66205 Contact: Kerry Hepler, RN    913-945-7552    ctnursenav@kumc.edu    Principal Investigator: Anup Kasi, MD          United States, Missouri University of Kansas Cancer Center - North Not yet recruiting Kansas City, Missouri, United States, 64154 Contact: kerr hepler    913-945-7552    ctnursenav@kumc.edu    Principal Investigator: Anup Kasi, MD          University of Kansas Cancer Center - Lee's Summit Not yet recruiting Lee's Summit, Missouri, United States, 64064 Contact: Kerry Hepler    913-945-7552    ctnursenav@kumc.edu Less <<
NCT03207347 Mesothelioma|Uveal Melanoma|Re... More >>nal Cell Carcinoma|Cholangiocarcinoma Less << PHASE2 COMPLETED 2022-08-30 University of Florida, Gainesv... More >>ille, Florida, 32610, United States|University of Miami, Miami, Florida, 33136, United States|Orlando Health UF Health Cancer Center, Orlando, Florida, 32806, United States Less <<
NCT02500901 Metastatic Prostate Cancer Phase 1 Terminated(Suspended by funder... More >>) Less << - United States, Massachusetts ... More >> Tufts Medical Center Boston, Massachusetts, United States, 02111 Less <<
NCT03759600 Ovarian Cancer|Fallopian Tube ... More >>Cancer|Primary Peritoneal Cancer Less << PHASE2 COMPLETED 2022-12-28 Aichi Cancer Center Hospital, ... More >>Nagoya, Aichi, Japan|Hirosaki University Hospital, Hirosaki, Aomori, Japan|National Cancer Center Hospital East, Kashiwa, Chiba, Japan|The Jikei University Kashiwa Hospital, Kashiwa, Chiba, Japan|Shikoku Cancer Center, Matsuyama, Ehime, Japan|Ehime University Hospital, Toon, Ehime, Japan|Kurume University Hospital, Kurume, Fukuoka, Japan|Kure Medical Center and Chugoku Cancer Center, Kure, Hiroshima, Japan|Hokkaido University Hospital, Sapporo, Hokkaido, Japan|Sapporo Medical University Hospital, Sapporo, Hokkaido, Japan|Hyogo Cancer Center, Akashi, Hyogo, Japan|Kansai Rosai Hospital, Amagasaki, Hyogo, Japan|Iwate Medical University Hospital, Morioka, Iwate, Japan|Tokai University Hospital, Isehara, Kanagawa, Japan|Nippon Medical School Musashi Kosugi Hospital, Kawasaki, Kanagawa, Japan|Mie University Hospital, Tsu, Mie, Japan|Tohoku University Hospital, Sendai, Miyagi, Japan|University of the Ryukyus Hospital, Nakagami-gun, Okinawa, Japan|Kindai University Hospital, Osakasayama, Osaka, Japan|Saitama Medical University International Medical Center, Hidaka, Saitama, Japan|Shizuoka Cancer Center, Nagaizumi-cho, Shizuoka, Japan|National Cancer Center Hospital, Chuo-ku, Tokyo, Japan|Cancer Institute Hospital, Koto-ku, Tokyo, Japan|The Jikei University Hospital, Minato-ku, Tokyo, Japan|Toho University Omori Medical Center, Ota-ku, Tokyo, Japan|Keio University Hospital, Shinjuku-ku, Tokyo, Japan|Chiba Cancer Center, Chiba, Japan|Chiba University Hospital, Chiba, Japan|Gifu University Hospital, Gifu, Japan|Kagoshima City Hospital, Kagoshima, Japan|Kyoto University Hospital, Kyoto, Japan|Nagasaki University Hospital, Nagasaki, Japan|Niigata University Medical & Dental Hospital, Niigata, Japan Less <<
NCT03497429 Advanced Solid Tumors PHASE1 COMPLETED 2020-02-10 National Cancer Center Hospita... More >>l, Chuo-ku, Tokyo, Japan Less <<
NCT03359850 Ovarian Neoplasms|Neoplasms|So... More >>lid Tumor|Hepatic Impairment Less << PHASE1 COMPLETED 2020-06-24 GSK Investigational Site, Los ... More >>Angeles, California, 90033, United States|GSK Investigational Site, Newport Beach, California, 92663, United States|GSK Investigational Site, Aurora, Colorado, 80045, United States|GSK Investigational Site, Atlanta, Georgia, 30322, United States|GSK Investigational Site, Houston, Texas, 77030, United States Less <<
NCT01110603 Cancer: Solid Tumors Phase 1 Terminated - -
NCT01847274 Platinum Sensitive Ovarian Can... More >>cer Less << Phase 3 Completed - -
NCT03586661 Deleterious BRCA1 Gene Mutatio... More >>n Deleterious BRCA2 Gene Mutation Endometrial Adenocarcinoma High Grade Ovarian Serous Adenocarcinoma Primary Peritoneal High Grade Serous Adenocarcinoma Recurrent Endometrial Carcinoma Recurrent Fallopian Tube Carcinoma Recurrent Ovarian Carcinoma Recurrent Primary Peritoneal Carcinoma Less << Phase 1 Not yet recruiting October 2020 United States, Texas ... More >> M D Anderson Cancer Center Not yet recruiting Houston, Texas, United States, 77030 Contact: N.       swestin@mdanderson.org Less <<
NCT03016338 Endometrial Cancer Phase 2 Recruiting September 2022 Canada, Alberta ... More >> Tom Baker Cancer Centre Recruiting Calgary, Alberta, Canada, T2N 4N2 Contact: Prafull Ghatage, M.D.    403-521-3721       Principal Investigator: Prafull Ghatage          Canada, Ontario Juravinski Cancer Centre Recruiting Hamilton, Ontario, Canada, L8V 5C2 Contact: Waldo Jimenez, M.D.    905-387-9495       Principal Investigator: Waldo Jimenez, M.D.          Cancer Centre of Southeastern Ontario at Kingston Recruiting Kingston, Ontario, Canada, K7L 5P9 Contact: Jim Biagi, M.D.    613-44-2630       Principal Investigator: Jim Biagi, M.D.          London Regional Cancer Centre Recruiting London, Ontario, Canada, N6A 4L6 Contact: Stephen Welch, M.D.    519-685-8640       Sunnybrook Research Institute, Sunnybrook Health Sciences Centre Recruiting Toronto, Ontario, Canada, M4N 3M5 Contact: Helen MacKay, M.D.    416-480-5145       Principal Investigator: Helen MacKay, M.D.          Princess Margaret Cancer Centre Recruiting Toronto, Ontario, Canada, M5G 1M9 Contact: Stephanie Lheureux, M.D.    416-946-2818       Principal Investigator: Stephanie Lheureux, M.D.          Canada, Quebec McGill University Health Centre - Glen Site Recruiting Montréal, Quebec, Canada, H3A 3J1 Contact: Lucy Gilbert, M.D.    514-934-1934 ext 34049       Principal Investigator: Lucy Gilbert, M.D. Less <<
NCT03154281 Breast Cancer ... More >> Ovarian Cancer Less << Phase 1 Recruiting June 2021 United States, South Dakota ... More >> Avera Cancer Institute Recruiting Sioux Falls, South Dakota, United States, 57105 Contact: Brian Leyland-Jones, MD    605-322-6900    brian.leylandjones@avera.org Less <<
NCT03329001 Solid Tumor Phase 1 Recruiting December 2019 United States, California ... More >> California Cancer Center for Research Excellence cCARE Recruiting Encinitas, California, United States, 92024 Principal Investigator: Alberto Bessudo, MD          United States, Georgia Winship Cancer Institute of Emory University Recruiting Atlanta, Georgia, United States, 30322 Principal Investigator: R. Donald Harvey, PharmD          United States, Tennessee Tennesse Oncology (SCRI) Recruiting Nashville, Tennessee, United States, 37203 Principal Investigator: Erika Hamilton, MD          United States, Texas MD Anderson Recruiting Houston, Texas, United States, 77030 Principal Investigator: Sarina Piha-Paul, MD          START- South Texas Accelerated Research Therapeutics, LLC Recruiting San Antonio, Texas, United States, 78229 Principal Investigator: Amita Patnaik, MD Less <<
NCT01905592 Carcinoma of Breast ... More >> Human Epidermal Growth Factor 2 Negative Carcinoma of Breast BRCA1 Gene Mutation BRCA2 Gene Mutation Less << Phase 3 Active, not recruiting May 2018 -
NCT03425201 Urothelial Cancer Phase 1 Phase 2 Not yet recruiting December 2019 Spain ... More >> ICO Badalona Badalona, Spain Hospital Clinic Barcelona, Spain Hospital de la Santa Creu i Sant Pau Barcelona, Spain ICO L'Hospitalet L'Hospitalet De Llobregat, Spain ICO L'Hospitalet Not yet recruiting L'Hospitalet De Llobregat, Spain Contact: Nuria Sala          Hospital 12 de Octubre Madrid, Spain Althaia Xarxa Not yet recruiting Manresa, Spain Contact: Montserrat Domenech          Instituto Valenciano de Oncología Valencia, Spain Less <<
NCT03759587 Ovarian Cancer|Fallopian Tube ... More >>Cancer|Primary Peritoneal Cancer Less << PHASE2 COMPLETED 2022-12-28 Aichi Cancer Center Hospital, ... More >>Nagoya, Aichi, Japan|Hirosaki University Hospital, Hirosaki, Aomori, Japan|Shikoku Cancer Center, Matsuyama, Ehime, Japan|Ehime University Hospital, Toon, Ehime, Japan|Kurume University Hospital, Kurume, Fukuoka, Japan|Hokkaido University Hospital, Sapporo, Hokkaido, Japan|Sapporo Medical University Hospital, Sapporo, Hokkaido, Japan|Hyogo Cancer Center, Akashi, Hyogo, Japan|Kansai Rosai Hospital, Amagasaki, Hyogo, Japan|Iwate Medical University Hospital, Morioka, Iwate, Japan|Tokai University Hospital, Isehara, Kanagawa, Japan|Nippon Medical School Musashi Kosugi Hospital, Kawasaki, Kanagawa, Japan|Mie University Hospital, Tsu, Mie, Japan|Tohoku University Hospital, Sendai, Miyagi, Japan|University of the Ryukyus Hospital, Nakagami-gun, Okinawa, Japan|Kindai University Hospital, Osakasayama, Osaka, Japan|Saitama Medical University International Medical Center, Hidaka, Saitama, Japan|Shizuoka Cancer Center, Nagaizumi-cho, Shizuoka, Japan|National Cancer Center Hospital, Chuo-ku, Tokyo, Japan|Cancer Institute Hospital, Koto-ku, Tokyo, Japan|The Jikei University Hospital, Minato-ku, Tokyo, Japan|Keio University Hospital, Shinjuku-ku, Tokyo, Japan|Chiba Cancer Center, Chiba, Japan|Kagoshima City Hospital, Kagoshima, Japan|Kyoto University Hospital, Kyoto, Japan|Nagasaki University Hospital, Nagasaki, Japan|Niigata University Medical & Dental Hospital, Niigata, Japan Less <<
NCT03076203 Prostate Carcinoma Metastatic ... More >>to the Bone Stage IV Prostate Adenocarcinoma Hormone-refractory Prostate Cancer Less << Phase 1 Recruiting November 2021 United States, Pennsylvania ... More >> Sidney Kimmel Cancer Center at Thomas Jefferson University Recruiting Philadelphia, Pennsylvania, United States, 19107 Contact: William Kelly, DO       william.kelly@jefferson.edu Less <<
NCT03209401 Solid Tumor, Adult ... More >> Homologous Recombination Deficiency Less << Phase 1 Recruiting July 2022 United States, District of Col... More >>umbia Lombardi Comprehensive Cancer Center Recruiting Washington, District of Columbia, United States, 20057 Contact: Laura Macke, RN    202-687-2111    lab228@georgetown.edu    Principal Investigator: Michael Pishvaian, MD, PhD          Principal Investigator: Claudine Isaacs, MD Less <<
NCT03601923 Pancreatic Cancer PHASE2 ACTIVE_NOT_RECRUITING 2026-02-28 Massachusetts General Hospital... More >>, Boston, Massachusetts, 02114, United States|Beth Israel Deaconess Medical Center, Boston, Massachusetts, 02215, United States|Dana Farber Cancer Institute, Boston, Massachusetts, 02215, United States Less <<
NCT03752216 Ovarian Cancer PHASE4 COMPLETED 2022-12-13 Sainte-Catherine Institut du C... More >>ancer Avignon-Provence, Avignon, 84918, France|Centre Hospitalier de la C?te Basque, Bayonne, 64109, France|CHRU Jean Minjoz, Besan?on, 25030, France|Clinique Tivoli, Bordeaux, 33000, France|Institut Bergonié, Bordeaux, 33076, France|H?pital Fleyriat, Bourg-en-bresse, 01012, France|Centre Fran?ois Baclesse, Caen, 14000, France|Medipole de Savoie, Challes-les-Eaux, 73190, France|SASU Centre d'Oncologie et Radiothérapie 37, Chambray-lès-Tours, 37170, France|Centre Jean Perrin, Clermont-Ferrand, 63000, France|Centre Georges Fran?ois Leclerc, Dijon, 21079, France|Groupe Hospitalier Mutualiste de Grenoble - Institut Daniel Hollard, Grenoble, 38028, France|Les H?pitaux de Chartres - H?pital Louis Pasteur, Le Coudray, 28630, France|H?pital Privé Jean Mermoz, Lyon, 69373, France|ICM Val d'Aurelle, Montpellier, 34298, France|Médip?le de NANCY / Centre d'Oncologie de Gentilly, Nancy, 54100, France|Centre Antoine Lacassagne, Nice, 06189, France|Centre ONCOGARD - Institut de Cancérologie du Gard, Nimes, 30029, France|Centre Hospitalier Régional d'Orléans, Orléans, 45000, France|H?pital Cochin, Paris, 75014, France|Groupe Hospitalier Diaconesses-Croix Saint Simon, Paris, 75020, France|Centre CARIO - HPCA, Plérin, 22190, France|Centre Hospitalier Universitaire de Poitiers, Poitiers, 86000, France|Institut du Cancer Courlancy, Reims, 51100, France|Centre Hospitalier Saint-Malo, Saint-Malo, 35400, France|Clinique Mutualiste de l'Estuaire, Saint-nazaire, 44600, France|CHU de Saint-Etienne - P?le de Cancérologie, Saint-Priest-en-Jarez, 42271, France|H?pitaux Universitaires de Strasbourg - Institut de Cancérologie Strasbourg Europe, Strasbourg, 67200, France|Clinique Pasteur, Toulouse, 31076, France|Institut de Cancérologie de Lorraine, Vand?uvre-lès-Nancy, 54519, France Less <<
NCT03644342 Metastatic Carcinoma of the Ce... More >>rvix Less << Phase 1 Phase 2 Not yet recruiting March 2, 2026 United States, Texas ... More >> Baylor College of Medicine Not yet recruiting Houston, Texas, United States, 77030 Contact: Michelle S Ludwig, MD, MPH, PhD    713-566-3757    Michelle.Ludwig@bcm.edu    Harris Health System - Smith Clinic Houston, Texas, United States, 77054 Less <<
NCT01294735 Recurrence of Solid Tumor ... More >> Glioblastoma Multiforme Melanoma Less << Phase 1 Completed - -
NCT03368729 Metastatic Breast Cancer ... More >> HER2 Positive Breast Carcinoma Less << Phase 1 Phase 2 Not yet recruiting November 1, 2021 United States, Alabama ... More >> University of Alabama at Birmingham Not yet recruiting Birmingham, Alabama, United States, 35294 Contact: Erica Stringer-Reasor, M.D.    205-934-2992    strinem@uab.edu Less <<
NCT01227941 Ovarian Cancer Phase 1 Terminated - -
NCT03329937 Neoplasms, Breast PHASE1 COMPLETED 2020-03-31 -
NCT00749502 Solid Tumors|Chronic Lymphocyt... More >>ic Leukemia|T-cell-prolymphocytic Leukemia Less << PHASE1 COMPLETED 2025-06-13 -
NCT01244009 Lymphoma|Mantle-Cell PHASE2 WITHDRAWN 2025-08-13 -
NCT01226901 Neoplasms|Solid Tumors PHASE1 TERMINATED 2025-11-11 -
NCT04992013 Metastatic Cancer|Central Nerv... More >>ous System Cancer Less << PHASE2 RECRUITING 2027-06-01 Massachusetts General Hospital... More >> Cancer Center, Boston, Massachusetts, 02114, United States|Brigham and Women's Hospital, Boston, Massachusetts, 02215, United States|Dana-Farber Cancer Institute, Boston, Massachusetts, 02215, United States Less <<
NCT05187208 Epithelial Ovarian Cancer|Ovar... More >>ian Cancer|Ovarian Cancer Stage III|Ovarian Cancer Stage IV Less << PHASE4 NOT_YET_RECRUITING 2025-12-25 -
NCT06086665 Epithelial Ovarian Cancer COMPLETED 2022-10-31 Department of Obstetrics and G... More >>ynecology, University of Ulsan College of Medicine, Asan Medical Center, Seoul, 138-736, Korea, Republic of Less <<
NCT04986371 Epithelial Ovarian Cancer NOT_YET_RECRUITING 2025-02-28 -
NCT05169437 Solid Tumor|Breast Tumor|Colon... More >> Tumor, Malignant|Lung Tumor|Urologic Cancer|Pancreatic Cancer|Melanoma|Metastatic Cancer|Locally Advanced Solid Tumor|Esophageal Cancer|Endometrial Cancer|Head and Neck Cancer Less << PHASE2 TERMINATED 2024-08-27 Yuma Regional Medical Center, ... More >>Yuma, Arizona, 85364, United States|Highlands Oncology, Springdale, Arkansas, 72762, United States|Memorial Care Medical Center, Fountain Valley, California, 92708, United States|St Joseph Heritage Health - Fullerton, Fullerton, California, 92835, United States|University of California San Diego, La Jolla, California, 92093-0698, United States|MemorialCare, Long Beach, California, 90806, United States|Cancer and Blood Specialty Clinic, Los Alamitos, California, 90720, United States|Cancer and Blood Specialty, Los Alamitos, California, 90720, United States|University of California Los Angeles, Los Angeles, California, 90404, United States|St Joseph Health Medical Group - Napa, Napa, California, 94558, United States|Ventura County Hematology Oncology Specialists, Oxnard, California, 93030, United States|Sharp Healthcare, San Diego, California, 92123, United States|Ridley-Tree Cancer Center, Santa Barbara, California, 93105, United States|St Joseph Health Medical Group - Santa Rosa, Santa Rosa, California, 95403, United States|Hartford Healthcare, Hartford, Connecticut, 06102, United States|Eastern Connecticut Hematology and Oncology, Norwich, Connecticut, 06360, United States|Holy Cross, Fort Lauderdale, Florida, 33308, United States|Cancer Specialists of North Florida, Jacksonville, Florida, 32256, United States|Ocala Community Cancer Center, Ocala, Florida, 34474, United States|University Cancer & Blood Center, Athens, Georgia, 30607, United States|Hawaii Cancer Care, Honolulu, Hawaii, 96813, United States|Rush University Medical Center, Chicago, Illinois, 60612, United States|Northwest Oncology & Hematology, Rolling Meadows, Illinois, 60008, United States|Fort Wayne Medical Oncology and Hematology, Fort Wayne, Indiana, 46845, United States|Goshen Health, Goshen, Indiana, 46526, United States|Community Health Network, Indianapolis, Indiana, 46250, United States|Beacon Health System, South Bend, Indiana, 46601, United States|Pontchartrain Cancer Center, Hammond, Louisiana, 70403, United States|The Center for Cancer and Blood Disorders - Maryland, Bethesda, Maryland, 20817, United States|Frederick Health, Frederick, Maryland, 21702, United States|Maryland Oncology Hematology, Rockville, Maryland, 20850, United States|Southcoast Health, Fairhaven, Massachusetts, 02719, United States|Sparrow Health, Lansing, Michigan, 48912, United States|Central Care Cancer Center, Bolivar, Missouri, 65613, United States|Mosaic Life Care, Saint Joseph, Missouri, 64507, United States|Oncology Hematology Associates, Springfield, Missouri, 65807, United States|Nebraska Cancer Specialists, Omaha, Nebraska, 68130, United States|OptumCare Cancer Care, Las Vegas, Nevada, 89102, United States|New Jersey Cancer Care and Blood Disorders, Belleville, New Jersey, 07109, United States|Englewood Health, Englewood, New Jersey, 07631, United States|Summit Medical Group, Florham Park, New Jersey, 07932, United States|Novant Health Inc. - Charlotte, Charlotte, North Carolina, 28204, United States|Southeastern Medical Oncology Center, Goldsboro, North Carolina, 27534, United States|Novant Health Inc. - Winston-Salem, Winston-Salem, North Carolina, 27103, United States|Aultman Medical Group, Canton, Ohio, 44708, United States|TriHealth, Cincinnati, Ohio, 45220, United States|University Hospitals Seidman, Cleveland, Ohio, 44106, United States|Cleveland Clinic - Taussig Cancer Center, Cleveland, Ohio, 44195, United States|OhioHealth, Columbus, Ohio, 43214, United States|The Toledo Clinic, Toledo, Ohio, 43623, United States|Oklahoma Cancer Specialists, Tulsa, Oklahoma, 74146, United States|Oregon Oncology Specialists, Salem, Oregon, 97301, United States|Gettysburg Cancer Center, Gettysburg, Pennsylvania, 17325, United States|Bon Secours - St. Francis Cancer Center, Greenville, South Carolina, 29607, United States|Avera Cancer Institute, Sioux Falls, South Dakota, 57105, United States|Sanford Health, Sioux Falls, South Dakota, 57117, United States|Baptist Cancer Center, Memphis, Tennessee, 38120, United States|Vanderbilt University, Nashville, Tennessee, 37232, United States|Texas Oncology - Austin Midtown, Austin, Texas, 78705, United States|Texas Oncology - Austin Central Pharmacy, Austin, Texas, 78731, United States|Texas Oncology - South Austin, Austin, Texas, 78745, United States|Mary Crowley Cancer Research, Dallas, Texas, 75230, United States|Texas Oncology - Baylor Charles A. Sammons Cancer Center, Dallas, Texas, 75246, United States|The University of Texas Southwestern Medical Center, Dallas, Texas, 75390, United States|Oncology Consultants, Houston, Texas, 77030, United States|Texas Oncology - Longview Cancer Center, Longview, Texas, 75601, United States|Texas Oncology - Palestine Cancer Center, Palestine, Texas, 75801, United States|Texas Oncology - Paris Cancer Center, Paris, Texas, 75460, United States|Lumi Research, Sugar Land, Texas, 77479, United States|Texas Oncology - Tyler Pharmacy, Tyler, Texas, 75702, United States|Community Cancer Trials of Utah, Ogden, Utah, 84405, United States|Utah Cancer Specialists, Salt Lake City, Utah, 84106, United States|Inova Schar Institute, Fairfax, Virginia, 22031, United States|Hematology Oncology Associates of Fredericksburg, Fredericksburg, Virginia, 22408, United States|Virginia Cancer Institute, Richmond, Virginia, 23229, United States|Virginia Cancer Institute, Richmond, Virginia, 23230, United States|PeaceHealth, Bellingham, Washington, 98225, United States|Northwest Medical Specialties, Tacoma, Washington, 98405, United States|ThedaCare, Appleton, Wisconsin, 54911, United States|SSM Health, Madison, Wisconsin, 53717, United States Less <<
NCT05021562 Ovarian Cancer ACTIVE_NOT_RECRUITING 2026-03-31 Takeda Selected Site, Tokyo, J... More >>apan Less <<
NCT04681469 Head and Neck Squamous Cell Ca... More >>rcinoma Less << PHASE2 RECRUITING 2025-06-28 Asst Degli Spedali Civili Di B... More >>rescia, Brescia, 25123, Italy Less <<
NCT04641247 Ovarian Neoplasms|Breast Neopl... More >>asms Less << PHASE2 ACTIVE_NOT_RECRUITING 2025-11-13 GSK Investigational Site, Tucs... More >>on, Arizona, 85710, United States|GSK Investigational Site, West Hollywood, California, 90048, United States|GSK Investigational Site, Whittier, California, 90603, United States|GSK Investigational Site, Jacksonville, Florida, 32224, United States|GSK Investigational Site, Atlanta, Georgia, 30342, United States|GSK Investigational Site, Harvey, Illinois, 60426, United States|GSK Investigational Site, Boston, Massachusetts, 02115, United States|GSK Investigational Site, Morristown, New Jersey, 07962-1956, United States|GSK Investigational Site, Lake Success, New York, 11042, United States|GSK Investigational Site, Charlotte, North Carolina, 28204, United States|GSK Investigational Site, Cleveland, Ohio, 44195, United States|GSK Investigational Site, Graz, A-8036, Austria|GSK Investigational Site, Wien, 1090, Austria|GSK Investigational Site, Vancouver, British Columbia, V5Z 4E6, Canada|GSK Investigational Site, Toronto, Ontario, M5G 2M9, Canada|GSK Investigational Site, Montreal, Quebec, H4A 3J1, Canada|GSK Investigational Site, Odense, 5000, Denmark|GSK Investigational Site, Nantes cedex, 44202, France|GSK Investigational Site, Nice Cedex 2, 06189, France|GSK Investigational Site, Haifa, 3109601, Israel|GSK Investigational Site, Cremona, Lombardia, 26100, Italy|GSK Investigational Site, Madrid, 28046, Spain|GSK Investigational Site, Marid, 28040, Spain Less <<
NCT05412706 Metastatic Colorectal Cancer PHASE2 WITHDRAWN 2023-09-04 -
NCT05961124 Ovarian Cancer|Stage III Ovari... More >>an Cancer|Stage IV Ovarian Cancer|High Grade Ovarian Serous Adenocarcinoma Less << PHASE2 RECRUITING 2025-09-27 Sunnybrook Research Institute,... More >> Toronto, Ontario, M4N3M5, Canada Less <<
NCT03925350 Metastatic Melanoma PHASE2 UNKNOWN 2025-02-23 California Pacific Medical Cen... More >>ter Research Institute, San Francisco, California, 94115, United States Less <<
NCT04715620 Recurrent Glioblastoma PHASE2 UNKNOWN 2025-01-23 Tianjin Huanhu Hosptal, Tianji... More >>n, Tianjin, 300350, China Less <<
NCT04785716 Ovarian Cancer|Peritoneal Canc... More >>er Less << COMPLETED 2020-08-03 Oslo University Hospital (OUH)... More >>, Oslo, 0379, Norway Less <<
NCT05297864 Recurrent Glioblastoma|Recurre... More >>nt Astrocytoma|Recurrent Oligodendroglioma|Recurrent Glioma Less << PHASE2 TERMINATED 2024-02-06 Stephenson Cancer Center, Okla... More >>homa City, Oklahoma, 73104, United States Less <<
NCT05515575 Sarcoma,Soft Tissue|Sarcoma Ut... More >>erus Less << PHASE2 ACTIVE_NOT_RECRUITING 2025-08-26 Memorial Sloan Kettering Cance... More >>r Center (Limited Protocol Activities), Basking Ridge, New Jersey, 07920, United States|Memorial Sloan Kettering Monmouth (Limited Protocol Activities), Middletown, New Jersey, 07748, United States|Memorial Sloan Kettering Bergen (Limited Protocol Activities), Montvale, New Jersey, 07645, United States|Memorial Sloan Kettering Cancer Center Suffolk- Commack (Limited Protocol Activities), Commack, New York, 11725, United States|Memorial Sloan Kettering Westchester (Limited Protocol Activities), Harrison, New York, 10604, United States|Memorial Sloan Kettering Cancer Center, New York, New York, 10065, United States|Memorial Sloan Kettering Nassau (Limited Protocol Activities), Uniondale, New York, 11553, United States Less <<
NCT05718323 SCLC,Extensive Stage|SLFN11-po... More >>sitive Less << PHASE2 RECRUITING 2025-10-25 CHU - Angers, Angers, France|C... More >>entre Hospitalier d'Avignon, Avignon, France|Caen - CHU, Caen, France|Lyon - Centre Léon Bérard, Lyon, France|Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori (IRST), Meldola, Italy|Instituto Europeo di Oncologia (IEO), Milan, Italy|Santa Maria della Misericordia Hospital, Perugia, Italy|AULSS2 Marca Trevigiana Treviso, Treviso, Italy|Medisprof Cancer Center, Cluj-Napoca, Romania|Complejo Hospitalario Universitario a Coru?a, A Coru?a, Spain|Complejo Hospitalario de Jaén, Jaén, Spain|Hospital Universitario Puerta de Hierro, Madrid, Spain|Kantonsspital Baden, Baden, Switzerland|University Hospital Basel, Basel, Switzerland|Inselspital Bern, Bern, Switzerland|Kantonsspital St. Gallen, Saint Gallen, Switzerland|Centre Hospitalier du Valais Romand, Sion, Switzerland|Bürgerspital Solothurn, Solothurn, Switzerland|Kantonsspital Winterthur, Winterthur, Switzerland Less <<
NCT04080284 Endometrial Cancer|Papillary S... More >>erous Endometrial Carcinoma|Uterine Serous Carcinoma|Endometrial Carcinoma|Cancer of the Endometrium Less << PHASE2 RECRUITING 2026-07-01 Rutgers Cancer Institute of Ne... More >>w Jersey, New Brunswick, New Jersey, 07103, United States|Imbert Cancer Center Northwell Health, Bay Shore, New York, 11706, United States|Greenlawn Cancer Institute, Northwell Health, Greenlawn, New York, 11740, United States|RJ Zuckerberg Cancer Hospital, New Hyde Park, New York, 11042, United States|Cancer Institute at Lenox Hill, New York, New York, 10075, United States Less <<
NCT05461690 Homologous Recombination Defic... More >>iency|Triple Negative Breast Cancer Less << PHASE2 NOT_YET_RECRUITING 2025-06-30 -
NCT06412120 Ovarian Cancer PHASE4 NOT_YET_RECRUITING 2030-04-01 University of Miami, Miami, Fl... More >>orida, 33136, United States Less <<
NCT05734911 Ovarian Neoplasms COMPLETED 2023-02-07 Zhongda hospital, Nanjing, 210... More >>009, China Less <<
NCT05232006 Metastatic Breast Cancer in Ge... More >>rmline-PALB2 Mutations Carriers Less << PHASE2 NOT_YET_RECRUITING 2025-05-30 -
NCT04217798 Ovarian Cancer PHASE2 UNKNOWN 2022-06-01 Peking Union Medical College H... More >>ospital, Beijing, China|Shandong Cancer Hospital, Jinan, China Less <<
NCT06141265 Ovarian, Fallopian Tube and Pr... More >>imary Peritoneal Carcinoma Less << PHASE2 RECRUITING 2025-09-27 Peking University Cancer Hospi... More >>tal, Beijing, Beijing, 100142, China Less <<
NCT05385068 Epithelial Ovarian Cancer PHASE2 UNKNOWN 2025-09-24 -
NCT04546373 Epithelial Ovarian Cancer|Fall... More >>opian Tube Cancer|Primary Peritoneal Cancer Less << COMPLETED 2021-07-31 Hospital Clínico Universitario... More >> de Santiago, Santiago De Compostela, A Coru?a, 15706, Spain|Hospital Virgen de los Lirios, Alcoy, Alicante, 03804, Spain|Hospital Marina Baixa, Villajoyosa, Alicante, 03570, Spain|Hospital Universitario Central de Asturias, Oviedo, Asturias, 33011, Spain|Institut Català d'Oncología Badalona, Badalona, Barcelona, 08916, Spain|Hospital General de Granollers, Granollers, Barcelona, 08402, Spain|Institut Català d′ Oncologia-Hospital Duran y Reynals, L'Hospitalet De Llobregat, Barcelona, 08908, Spain|Consorci Sanitari de Terrassa, Rubí, Barcelona, 08191, Spain|Consorci Corporació Sanitària Parc Taulí de Sabadell, Sabadell, Barcelona, 08208, Spain|Hospital Universitario de Galdakao, Galdakao, Bizkaia, 48960, Spain|Hospital Universitario Marqués de Valdecilla, Santander, Cantabria, 39008, Spain|Hospital Provincial de Castellón, Castelló de la Plana, Castellón, 12002, Spain|Hospital Universitario de Jerez, Jerez De La Frontera, Cádiz, 11407, Spain|Hospital Universitario Donostia, San Sebastián, Gipuzkoa, 20014, Spain|Hospital Universari Son Espases, Palma De Mallorca, Islas Baleares, 07120, Spain|Hospital Universitario Fundación Alcorcón, Alcorcón, Madrid, 28922, Spain|Hospital Universitario Puerta de Hierro, Majadahonda, Madrid, 28222, Spain|Hospital Universitario Infanta Sofia, San Sebastián De Los Reyes, Madrid, 28702, Spain|Hospital álvaro Cunqueiro, Vigo, Pontevedra, 36213, Spain|Hospital Lluís Alcanyís de Xàtiva, Xàtiva, Valencia, 46800, Spain|Hospital Universitario de Basurto, Bilbao, Vizcaya, 48013, Spain|Complejo Hospitalario Universitario A Coru?a (Juan Canalejo), A Coru?a, 15006, Spain|Hospital Universitari Sant Joan d'Alacant, Alicante, 03550, Spain|Hospital Universitario Torrecárdenas, Almería, 04009, Spain|Hospital del Mar, Barcelona, 08003, Spain|Clínica Corachan, Barcelona, 08017, Spain|Hospital Universitari Dexeus - Grupo Quirónsalud, Barcelona, 08028, Spain|Hospital Clínic i Provincial de Barcelona, Barcelona, 08036, Spain|Hospital de la Santa Creu i Sant Pau, Barcelona, 08041, Spain|Hospital San Pedro de Alcántara, Cáceres, 10003, Spain|Hospital Universitario Puerta del Mar, Cádiz, 11009, Spain|Hospital Universitario Reina Sofía, Córdoba, 14004, Spain|Hospital Universitario Clínico San Cecilio, Granada, 18016, Spain|Hospital Universitario de Guadalajara, Guadalajara, 19002, Spain|Hospital General San Jorge, Huesca, 22004, Spain|Complejo Hospitalario de Jaén - Hospital Médico-Quirúrgico, Jaén, 23007, Spain|Hospital Universitari Arnau de Vilanova, Lleida, 25198, Spain|Hospital Universitario de La Princesa, Madrid, 28006, Spain|Clínica Universidad de Navarra, Madrid, 28027, Spain|MD Anderson Cancer Center Madrid, Madrid, 28033, Spain|Hospital Universitario Ramón y Cajal, Madrid, 28034, Spain|Hospital Clínico San Carlos, Madrid, 28040, Spain|Hospital Universitario 12 De Octubre, Madrid, 28041, Spain|Hospital Universitario La Paz, Madrid, 28046, Spain|Hospital Universitario HM Sanchinarro, Madrid, 28050, Spain|Complejo Hospitalario Universitario de Pontevedra (Hospital Montecelo), Pontevedra, 36071, Spain|Hospital Clínico Universitario de Salamanca, Salamanca, 37007, Spain|Hospital Universitario Nuestra Se?ora de Candelaria, Santa Cruz De Tenerife, 38010, Spain|Hospital Quirónsalud Sagrado Corazón, Sevilla, 41013, Spain|Hospital Universitario Virgen del Rocio, Sevilla, 41013, Spain|Hospital Universitario de Valme, Sevilla, 41014, Spain|Consorcio Hospital General Universitario de Valencia, Valencia, 46014, Spain|Hospital Universitario Doctor Peset, Valencia, 46017, Spain|Hospital Universitari i Politècnic La Fe, Valencia, 46026, Spain|Hospital Clínico Universitario de Valladolid, Valladolid, 47003, Spain|Hospital Clínico Universitario Lozano Blesa, Zaragoza, 50009, Spain|Hospital Universitario Miguel Servet, Zaragoza, 50009, Spain Less <<
NCT04507841 Ovarian Cancer PHASE2 ACTIVE_NOT_RECRUITING 2026-12-31 Tongji Hospital, Wuhan, Hubei,... More >> 430000, China Less <<
NCT04284852 Ovarian Cancer PHASE2 COMPLETED 2023-10-01 The University of Hong Kong, H... More >>ong Kong, Hong Kong Less <<
NCT04716686 Endometrial Carcinoma|Serous C... More >>arcinoma Less << PHASE2 RECRUITING 2026-12-31 Qilu Hospital of Shandong Univ... More >>ersity, Jinan, Shandong, 250012, China Less <<
NCT03840967 Esophageal Cancer|Gastric Canc... More >>er|Adenocarcinoma Less << PHASE2 TERMINATED 2023-02-22 Moffitt Cancer Center, Tampa, ... More >>Florida, 33612, United States|Indiana Univeristy Melvin and Bren Simon Cancer Center, Indianapolis, Indiana, 46202, United States|University of Michigan Health System, Ann Arbor, Michigan, 48109, United States|Roswell Park Cancer Institute, Buffalo, New York, 14263, United States Less <<
NCT05442749 Metastatic Pancreatic Cancer PHASE2 WITHDRAWN 2026-09-15 Centre Léon Bérard, Lyon, Fran... More >>ce Less <<
NCT06237205 Efficacy PHASE2 NOT_YET_RECRUITING 2027-06-30 -
NCT03891576 Ovarian Cancer|Fallopian Tube ... More >>Cancer|Primary Peritoneal Carcinoma Less << PHASE2 TERMINATED 2024-08-31 Charité - Universit?tsmedizin ... More >>Berlin, Berlin, Germany|University Hospital Dresden, Dresde, Germany|Kliniken Essen Mitte, Essen, Germany|ASST degli Spedali Civili di Brescia, Brescia, Italy|Istituto Nazionale dei Tumori, Milano, Italy|Istituto Europeo di Oncologia, Milan, Italy|Ospedale San Gerardo, Monza, Italy|Istituto Oncologico Veneto (IOV), Padova, Italy|AO Arcispedale Santa Maria Nuova, Reggio Emilia, Italy|Policlinico Umberto I, Università di Roma "La Sapienza", Roma, Italy|AO Ordine Mauriziano, Torino, Italy|AOU Città della Salute e della Scienza di Torino - Ospedale Sant'Anna, Torino, Italy Less <<

Protocol

Bio Calculators
Preparing Stock Solutions 1mg 5mg 10mg

1 mM

5 mM

10 mM

3.12mL

0.62mL

0.31mL

15.61mL

3.12mL

1.56mL

31.21mL

6.24mL

3.12mL

Dissolving Methods
Please choose the appropriate dissolution scheme according to your animal administration guide.For the following dissolution schemes, clear stock solution should be prepared according to in vitro experiments, and then cosolvent should be added in turn:

in order to ensure the reliability of the experimental results, the clarified stock solution can be properly preserved according to the storage conditions; The working fluid for in vivo experiment is recommended to be prepared now and used on the same day;

The percentage shown in front of the following solvent refers to the volume ratio of the solvent in the final solution; If precipitation or precipitation occurs in the preparation process, it can be assisted by heating and/or ultrasound.
Protocol 1
Protocol 2

References

 

Historical Records

Categories